Cargando…

Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity

The biological relationships among self-renewal, tumorigenicity, and lineage differentiation of human osteosarcoma-initiating cells (OSIC) remain elusive, making it difficult to identify and distinguish OSIC from osteosarcoma-forming cells (OSFC) for developing OSIC-targeted therapies. Using a new i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Meidan, Liu, Gang, Shimada, Hiroyuki, Ding, Wanjing, May, William A., He, Qiaojun, Adams, Gregor B., Wu, Lingtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947577/
https://www.ncbi.nlm.nih.gov/pubmed/23045288
http://dx.doi.org/10.1038/onc.2012.438
_version_ 1782306701604552704
author Ying, Meidan
Liu, Gang
Shimada, Hiroyuki
Ding, Wanjing
May, William A.
He, Qiaojun
Adams, Gregor B.
Wu, Lingtao
author_facet Ying, Meidan
Liu, Gang
Shimada, Hiroyuki
Ding, Wanjing
May, William A.
He, Qiaojun
Adams, Gregor B.
Wu, Lingtao
author_sort Ying, Meidan
collection PubMed
description The biological relationships among self-renewal, tumorigenicity, and lineage differentiation of human osteosarcoma-initiating cells (OSIC) remain elusive, making it difficult to identify and distinguish OSIC from osteosarcoma-forming cells (OSFC) for developing OSIC-targeted therapies. Using a new inverse lineage tracking strategy coupled with serial human-to-mouse xenotransplantation, we identified a subpopulation of osteosarcoma cells with OSIC-like properties and sought to distinguish them from their progeny, OSFC. We found that serial transplantation of cells from different osteosarcoma cell lines and primary osteosarcoma tissues progressively increased the CD49f(+) subpopulation composing the bulk of the osteosarcoma mass. These CD49f(+) cells displayed characteristics of OSFC: limited in vivo tumorigenicity, weak lineage differentiation, more differentiated osteogenic feature, and greater chemo-sensitivity. By contrast, their parental CD49f(−)CD133(+) cells had an inhibited osteogenic fate, together with OSIC-like properties of self-renewal, strong tumorigenicity, and differentiation to CD49f(+) progeny. Hence, the CD49f(−)CD133(+) phenotype appears to identify OSIC-like cells that possess strong tumorigenicity correlated with an impaired osteogenic fate and the ability to initiate tumor growth through generation of CD49f(+) progeny. These findings advance our understanding of OSIC-like properties and, for the first time, provide a much-needed distinction between OSIC and OSFC in this cancer.
format Online
Article
Text
id pubmed-3947577
institution National Center for Biotechnology Information
language English
publishDate 2012
record_format MEDLINE/PubMed
spelling pubmed-39475772014-03-09 Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity Ying, Meidan Liu, Gang Shimada, Hiroyuki Ding, Wanjing May, William A. He, Qiaojun Adams, Gregor B. Wu, Lingtao Oncogene Article The biological relationships among self-renewal, tumorigenicity, and lineage differentiation of human osteosarcoma-initiating cells (OSIC) remain elusive, making it difficult to identify and distinguish OSIC from osteosarcoma-forming cells (OSFC) for developing OSIC-targeted therapies. Using a new inverse lineage tracking strategy coupled with serial human-to-mouse xenotransplantation, we identified a subpopulation of osteosarcoma cells with OSIC-like properties and sought to distinguish them from their progeny, OSFC. We found that serial transplantation of cells from different osteosarcoma cell lines and primary osteosarcoma tissues progressively increased the CD49f(+) subpopulation composing the bulk of the osteosarcoma mass. These CD49f(+) cells displayed characteristics of OSFC: limited in vivo tumorigenicity, weak lineage differentiation, more differentiated osteogenic feature, and greater chemo-sensitivity. By contrast, their parental CD49f(−)CD133(+) cells had an inhibited osteogenic fate, together with OSIC-like properties of self-renewal, strong tumorigenicity, and differentiation to CD49f(+) progeny. Hence, the CD49f(−)CD133(+) phenotype appears to identify OSIC-like cells that possess strong tumorigenicity correlated with an impaired osteogenic fate and the ability to initiate tumor growth through generation of CD49f(+) progeny. These findings advance our understanding of OSIC-like properties and, for the first time, provide a much-needed distinction between OSIC and OSFC in this cancer. 2012-10-08 2013-09-05 /pmc/articles/PMC3947577/ /pubmed/23045288 http://dx.doi.org/10.1038/onc.2012.438 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Ying, Meidan
Liu, Gang
Shimada, Hiroyuki
Ding, Wanjing
May, William A.
He, Qiaojun
Adams, Gregor B.
Wu, Lingtao
Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
title Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
title_full Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
title_fullStr Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
title_full_unstemmed Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
title_short Human osteosarcoma CD49f(−)CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
title_sort human osteosarcoma cd49f(−)cd133(+) cells: impaired in osteogenic fate while gain of tumorigenicity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947577/
https://www.ncbi.nlm.nih.gov/pubmed/23045288
http://dx.doi.org/10.1038/onc.2012.438
work_keys_str_mv AT yingmeidan humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT liugang humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT shimadahiroyuki humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT dingwanjing humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT maywilliama humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT heqiaojun humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT adamsgregorb humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity
AT wulingtao humanosteosarcomacd49fcd133cellsimpairedinosteogenicfatewhilegainoftumorigenicity